microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer
- PMID: 21737487
- DOI: 10.1158/0008-5472.CAN-11-0489
microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer
Abstract
microRNA expression profiling plays an emerging role in cancer classification and identification of therapeutic strategies. In this study, we have evaluated the benefits of a joint microRNA-mRNA analysis in breast cancer. Matched mRNA and microRNA global expression profiling was conducted in a well-annotated cohort of 207 cases with complete 10-year follow-up. Penalized Cox regression including microRNA expression, mRNA expression, and clinical covariates was used to identify microRNAs associated with distant relapse-free survival (DRFS) that provide independent prognostic information, and are not simply surrogates of previously identified prognostic covariates. Penalized regression was chosen to prevent overfitting. Furthermore, microRNA-mRNA relationships were explored by global expression analysis, and exploited to validate results in several published cohorts (n = 592 with DRFS, n = 1,050 with recurrence-free survival). Four microRNAs were independently associated with DRFS in estrogen receptor (ER)-positive (3 novel and 1 known; miR-128a) and 6 in ER-negative (5 novel and 1 known; miR-210) cases. Of the latter, miR-342, -27b, and -150 were prognostic also in triple receptor-negative tumors. Coordinated expression of predicted target genes and prognostic microRNAs strengthened these results, most significantly for miR-210, -128a, and -27b, whose targets were prognostic in meta-analysis of several cohorts. In addition, miR-210 and -128a showed coordinated expression with their cognate pri-microRNAs, which were themselves prognostic in independent cohorts. Our integrated microRNA-mRNA global profiling approach has identified microRNAs independently associated with prognosis in breast cancer. Furthermore, it has validated known and predicted microRNA-target interactions, and elucidated their association with key pathways that could represent novel therapeutic targets.
©2011 AACR
Comment in
-
Integrated analysis of miRNA and mRNA profiles enables target acquisition in human cancers.Expert Rev Anticancer Ther. 2012 Mar;12(3):323-30. doi: 10.1586/era.12.11. Expert Rev Anticancer Ther. 2012. PMID: 22369323
Similar articles
-
Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.PLoS One. 2013;8(2):e55910. doi: 10.1371/journal.pone.0055910. Epub 2013 Feb 6. PLoS One. 2013. PMID: 23405235 Free PMC article.
-
Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.EBioMedicine. 2016 Sep;11:199-209. doi: 10.1016/j.ebiom.2016.08.016. Epub 2016 Aug 17. EBioMedicine. 2016. PMID: 27566954 Free PMC article.
-
MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.Breast Cancer Res Treat. 2014 Aug;147(1):39-49. doi: 10.1007/s10549-014-3069-5. Epub 2014 Aug 3. Breast Cancer Res Treat. 2014. PMID: 25086633
-
Prognostic role of microRNA-210 in various carcinomas: a systematic review and meta-analysis.Dis Markers. 2014;2014:106197. doi: 10.1155/2014/106197. Epub 2014 Jan 23. Dis Markers. 2014. PMID: 24591754 Free PMC article. Review.
-
Breast cancer and microRNAs: therapeutic impact.Breast. 2011 Oct;20 Suppl 3:S63-70. doi: 10.1016/S0960-9776(11)70297-1. Breast. 2011. PMID: 22015296 Review.
Cited by
-
Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers.PLoS One. 2012;7(11):e48692. doi: 10.1371/journal.pone.0048692. Epub 2012 Nov 7. PLoS One. 2012. PMID: 23144930 Free PMC article.
-
MicroRNA regulation of molecular pathways as a generic mechanism and as a core disease phenotype.Oncotarget. 2015 Jan 30;6(3):1594-604. doi: 10.18632/oncotarget.2734. Oncotarget. 2015. PMID: 25593195 Free PMC article.
-
miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer.Sci Rep. 2016 Sep 7;6:32541. doi: 10.1038/srep32541. Sci Rep. 2016. PMID: 27600857 Free PMC article.
-
Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations.Oncologist. 2020 Jan;25(1):e16-e23. doi: 10.1634/theoncologist.2019-0123. Epub 2019 Aug 1. Oncologist. 2020. PMID: 31371522 Free PMC article.
-
MVDA: a multi-view genomic data integration methodology.BMC Bioinformatics. 2015 Aug 19;16:261. doi: 10.1186/s12859-015-0680-3. BMC Bioinformatics. 2015. PMID: 26283178 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases